Chemistry: molecular biology and microbiology – Vector – per se
Patent
1995-02-14
2000-03-21
Campell, Bruce R.
Chemistry: molecular biology and microbiology
Vector, per se
435455, 435456, 435457, 435 691, 435 698, 435325, 424 9321, 514 44, 800 9, C12N 1563, C12N 1500, C12N 1509, C12N 500
Patent
active
060401729
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD OF THE INVENTION
The present invention relates to the field of neurobiology and, more particularly, to the diagnosis and treatment of various neural dysfunctions and disabilities by the direct introduction of genetic material. The invention further relates to the introduction of genetic material in somatic cells.
BACKGROUND OF THE INVENTION
The study of molecular neurobiology has developed with a view to implementing specific, effective therapeutic strategies to treat neural debilitation. Classically, three technical approaches have been followed to the present. The first, comprising the cloning and sequencing of novel cDNAs, seeks to develop specific genes that may be subsequently introduced in vivo to mediate and thereby achieve physiological alterations. The second strategy of molecular hybridization for the purpose of studying expression and regulation of specific messenger RNAs, likewise seeks to promote modifications through transcription. By contrast, the third strategy, involving direct manipulation of neuronal expression in vivo, seeks to actively alter neuronal cell physiology.
Two strategies that have been investigated in the direct approach involve the development of a transgenic vehicle, and efforts to deliver specific genes by incorporation within a viral vector that is delivered directly to the neuronal population of interest for in vivo expression. The former approach has been limited somewhat by corresponding limitation in the choice of species that are amenable to transgenic manipulations. Also, the transgenic approach has failed to provide the necessary specificity and selectively that is requisite for effective use. Tissue-specific promoters have been applied to this effect and have achieved some level of success [Forss-Petter et al. (1990) NEURON., 5:187-197; Oberdick et al. (1990) SCIENCE, 248:223-226]. Even with this degree of selectively, however, expression in all cell types in which a given promoter is active is still unavoidable.
The use of viral constructs is the subject of extensive study, and particularly, with respect to the exploration of such a construct involving a defective herpes simplex viral vector based on a plasmid called an amplicon [Kaplitt et al. (1991) MOL. CELL. NEUROSCI., 2:320-330; Spaete et al. (1982) CELL, 30:295-304; Geller et al. (1988) SCIENCE, 241:1667-1669]. Herpes simplex virus type 1 (HSV1) has been favored because of its broad host and tissue ranges. Several investigators including the present inventor have experimented with the incorporation into HSV1 vectors, and particularly defective viral vectors, various foreign genes for direct neuronal introduction in vivo. While such efforts have been pursued, and in particular, efforts with the lac Z gene of E. coli [Geller et al. supra], none of the vectors developed and used have ever resulted in stable expression, by which is meant expression in excess of two weeks of a gene introduced in a defective HSV vector.
Other investigators have pursued gene transfer in vivo by use of an HSV whole viral vector [see generally, Breakefield et al. (1991) NEW BIOL., 3(3):203-218]. Successful genetic transfer in vivo has been achieved with these vectors [Dobson et al. (1990) NEURON, 5:353-360; Chiocca et al. (1990) NEW BIOL., 2:739-746; Fink et al. (1992) HUMAN GENE THER., 3:11-19]. While all of the noted investigators observed expression after introduction with the whole viral vector, expression ceased after two weeks in two instances and extended to five weeks and then ceased in the third [Dobson et al., supra]. In this latter connection, Dobson et al. noted that the lac Z gene was placed under the control of the viral promoter, and that the normal viral gene does not express during HSV latency, so that the cessation of expression after five weeks was attributed to cessation of promoter activity upon the entry of the viral DNA into a latent state.
As the potential value of stable and long-term expression of foreign genes in target neuronal populations and, particularly, in the brain, holds great
REFERENCES:
patent: 4546082 (1985-10-01), Kurjan et al.
patent: 5288641 (1994-02-01), Roizman
Andersen et al., Society for Neuroscience Abstracts, vol. 17, Abstract No. 570.6, 1991.
Kaplitt et al., Neurobiology, vol. 91, pp. 8979-8983, Sep. 1994.
Eck & Wilson, `Gene-Based Therapy` in Goodman & Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill: New York, pp. 77-101, 1995.
Houdebine, Journal of Biotechnology, vol. 34, pp. 269-287, 1994.
Eliot Marshal. Gene Therapy's Growing Pains. Science. vol. 269 (1995) p1050-1055, Aug. 25, 1995.
Clague P. Hodgson. Advances in Vector Systems For Gene Therapy. Exp. Opin. Ther. Patents (1995) 5 (5) p. 459-460.
Fred D. Ledley. Clinical Considerations in the Design of Protocols for Somatic Gene Therapy. Human Gene Therapy 2:77-83 (1991).
Orkin, S.H.; Motulsky, A.G. Report and Recomendations of the Panel to Assess the NIH Investment in Research on Gene Therapy. NIH Dec. 7, 1995.
Hatsoglou et al. The Journal of Biological Chemistry. vol. 265 No. 28 pp. 17285-17293, Oct. 5, 1990.
Donovan et al., 1992, Proc. Natl. Acad. Sci. USA89:2345-49.
Federoff et al., 1992, Proc. Natl. Acad. Sci. USA 89 1636-40.
Fink et al., 1992, Human Gene Ther. 3:11-19.
Huang et al., 1992, Exp. Neurol. 115:303-16.
Johnson et al., 1992, Mol. Brain Res. 12:95-102.
Kaplitt et al., 1992, Neurosci. Abstracts 10:500 & 22nd Annual Meeting of the Society for Neuroscience, Anaheim, USA, Oct. 25-30, 1992.
Miyanohara et al., 1992, New Biol. 4:238-46.
Neve et al., 1992, Mol. Neurobiology 5:131-41.
Breakefield et al., 1991, New Biol. 3:203-218.
Kaplitt et al., 1991, Mol. Cell. Neurosci. 2:320-330.
Geller, 1991, J. Vir. Meth. 31:229-38.
Geller, 1991, J. Neuroscience Meth. 36:91-103.
Geller et al., 1991, TINS 14:428-32.
Kaplitt et al., 1991, Soc. Neurosci. Abs. 17:1285 (No.513.3).
Mellencamp et al., 1991, Clin Res. 39:705a.
Chiocca et al., 1990, New Biol. 2:739-746.
Dobson et al., 1990, Neuron 5:353-360.
Freese et al., 1990, Biochem. Pharmacol. 40:2189-99.
Geller et al., 1990, Proc. Natl. Acad. Sci. USA 87:8950-54.
Geller et al., 1990, Proc. Natl. Acad. Sci. USA 87:1149-53.
Boothman et al., 1989, FEBS Letts. 258:159-62.
Coen et al., 1989, Proc. Natl. Acad. Sci USA 86:4736-40.
Geller et al., 1988, Science 241:1667-1669.
Ho et al., 1988, Virology 167:279-83.
Kwong et al., 1985, Virology 142:421-25.
Kwong et al., 1984, J. Virol. 51:595-603.
Frenkl et al., 1982, Eukaryotic Viral Vectors, Gluman, ed., Cold Spring Harbor Lab., pp. 205-9.
Spaete et al., 1982, Cell 30:295-304.
Campell Bruce R.
Martin Jill D.
The Rockefeller University
LandOfFree
Defective DNA viral vector comprising a neural tissue-specific p does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Defective DNA viral vector comprising a neural tissue-specific p, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Defective DNA viral vector comprising a neural tissue-specific p will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-729720